A trial of LM-302 with tislelizumab for stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with adenocarcinoma of the stomach or the junction of the stomach and esophagus.
- Your cancer has spread or cannot be surgically removed, and you have not had any previous treatment for this stage of cancer.
- You must be willing to provide a tumor sample for testing a protein called CLDN18.2 (a positive result is needed).
- Your tumor must be negative for a protein called HER2 (determined by a previous lab test).
- Good overall health: able to walk and care for yourself (ECOG score 0 or 1), and have adequate organ function (kidney, liver, heart, blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Hear when a new Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.